Related Experiment Video
Updated: Aug 8, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Cancer vaccines
1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Abstract:
1993 represents the 100th anniversary of William Coley's first report of tumour regressions induced by immune system activation in response to bacterial toxins. While many subsequent cancer vaccine trials have yielded tantalizing results, active immunotherapy has not yet become an established modality of cancer therapy. Drew Pardoll reviews newer molecular vaccine approaches based on rational immunological principles that have resulted in improved systemic antitumour effects in animal models. Ultimately the genetic definition of tumour-specific antigens will allow the development of targeted antigen-specific vaccines for cancer therapy.
Insights
Cancer immunotherapy, a century after its inception, shows promise with new molecular vaccine approaches. Identifying tumor-specific antigens is key to developing targeted cancer vaccines for effective therapy.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- William Coley's 1893 report marked the centenary of using bacterial toxins for immune-mediated tumor regression.
- Despite early promise, active immunotherapy has not yet become a standard cancer treatment modality.
- Recent advancements focus on molecular vaccine approaches grounded in immunological principles.
Purpose of the Study:
- To review emerging molecular vaccine strategies for cancer therapy.
- To highlight approaches demonstrating improved systemic anti-tumor effects in preclinical models.
- To discuss the future potential of antigen-specific cancer vaccines.
Main Methods:
- Review of recent literature on molecular cancer vaccine development.
- Analysis of studies employing rational immunological principles.
- Examination of preclinical data from animal models showing anti-tumor effects.
Main Results:
- Newer molecular vaccine approaches show improved systemic anti-tumor effects in animal models.
- These strategies are based on established immunological principles.
- The field is moving towards more targeted and specific therapeutic interventions.
Conclusions:
- Molecular vaccine strategies represent a promising evolution in active cancer immunotherapy.
- The identification of tumor-specific antigens is crucial for developing targeted, effective cancer vaccines.
- Further research in this area holds significant potential for future cancer treatment.
Related Concept Videos
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

